Washington Post: Quest for new antibiotics gets first major funding from global partnership
“A major global partnership aimed at fighting superbugs announced Thursday that it is investing up to $48 million in research projects, including potentially the first new classes of antibiotics in decades, to target the deadliest drug-resistant bacteria. The investments announced by CARB-X include $24 million in immediate funding for 11 companies. The firms can receive up to $24 million in additional payments over three years if they meet specific milestones. … Funding comes from the Biomedical Advanced Research and Development Authority, or BARDA, part of the Department of Health and Human Services, and the Wellcome Trust, a London-based global biomedical research charity…” (Sun, 3/30).